{"DataElement":{"publicId":"3646385","version":"1","preferredName":"Mitotane Therapy Administered Gross Residual And/Or Non-Resectable Disease Indicator","preferredDefinition":"Indicator to signify whether or not mitotane therapy was given for macroscopic residual disease and/or non-resectable disease.","longName":"3646309v1.0:3506034v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3646309","version":"1","preferredName":"Therapeutic Procedure Gross Residual And/Or Non-Resectable Disease Mitotane Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Visible to the naked eye._Cancer cells that remain after attempts to remove the cancer have been made._Used to indicate that either or both of two items or options may be valid._An operation in which a term denies or inverts the meaning of another term or construction._The act of cutting out; the surgical removal of part or all of a structure or organ._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)_The act of having given something (e.g., a medication or test).","longName":"2512834v1.0:3646307v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3646307","version":"1","preferredName":"Gross Residual Disease And/Or Negation Excision Malignant Neoplasm Mitotane Administered","preferredDefinition":"Visible to the naked eye.:Cancer cells that remain after attempts to remove the cancer have been made.:Used to indicate that either or both of two items or options may be valid.:An operation in which a term denies or inverts the meaning of another term or construction.:The act of cutting out; the surgical removal of part or all of a structure or organ. :A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04):The act of having given something (e.g., a medication or test).","longName":"3646307v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gross","conceptCode":"C43566","definition":"Visible to the naked eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Residual Disease","conceptCode":"C4809","definition":"Tumor cells that remain in the body following cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Excision","conceptCode":"C15232","definition":"The surgical removal of a lesion, often as part of a biopsy and with healthy margins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mitotane","conceptCode":"C664","definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13AD5AD-CFEC-B08A-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-12-19","modifiedBy":"ONEDATA","dateModified":"2012-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13AD5AD-CFFD-B08A-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-12-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TCGA Mesothelioma form and released per approval by T.Lichtenberg. mc 1/4/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506034","version":"1","preferredName":"Yes No Unknown Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"YES_NO_UNKNOWN_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D05-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D0F-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D1A-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2548260","version":"1","preferredName":"Ind-3","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"C38148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Unknown Response","conceptCode":"C38148","definition":"A response or indicator that can have a value of yes, no, or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"23801A33-5B13-534B-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2006-11-30","endDate":"2016-04-27","createdBy":"BIRNBAUA","dateCreated":"2006-11-30","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 4-27-2016 per Tina Taylor approved by Dianne Reeves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C379D9D0-6CF1-CCDD-E040-BB89AD432590","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TITARENI","dateModified":"2021-09-14","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 3/35/2016 jk removed \"indeterminate\" value that was added in error. 7/7/2021wz: added ALT VM name for HOPE-CARE project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did the patient receive mitot","type":"Preferred Question Text","description":"Did the patient receive mitotane therapy for macroscopic residual disease and/or non-resectable disease?","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D13CFD78-D94C-5CFE-E040-BB89AD436F0C","latestVersionIndicator":"Yes","beginDate":"2012-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-12-19","modifiedBy":"TSESU","dateModified":"2018-07-16","changeDescription":"Created for TCGA Mesothelioma form and released per approval by T.Lichtenberg. mc 1/4/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}